Please use this identifier to cite or link to this item: doi:10.22028/D291-39780
Title: Low Vitamin D Status Predicts Poor Clinical Outcome in Advanced Melanoma Treated With Immune Checkpoint or BRAF/MEK Inhibitors: A Prospective Non-Interventional Side-by-Side Analysis
Author(s): Reichrath, Jörg
Biersack, Florian
Wagenpfeil, Stefan
Schöpe, Jakob
Pföhler, Claudia
Saternus, Roman
Vogt, Thomas
Language: English
Title: Frontiers in oncology
Volume: 12
Publisher/Platform: Frontiers
Year of Publication: 2022
Free key words: BRAF/MEK inhibitor
advanced melanoma
immune checkpoint inhibitor
low vitamin D status
vitamin D
vitamin D status
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: In melanoma and other malignancies, low vitamin D status is associated with increased risk and poor prognosis. However, there are limited data of the impact of 25(OH)D serum concentration (s.c.) on clinical outcome in advanced melanoma. We tested the hypothesis that vitamin D status is predictive of efficacy and safety in patients treated for metastasized melanoma with B-rapidly accelerated fibrosarcoma (BRAF), mitogen-activated protein kinase kinase (MEK), cytotoxic T lymphocyte-associated protein-4 (CTLA-4), and/or programmed cell death protein-1 (PD-1) inhibitors. Severe vitamin D deficiency [defined as 25(OH)D s.c. <10 ng/ml] was associated with markedly reduced overall (OS) and progress-free (PFS) survival, with increased tumor load [TL; measured as s.c. of S100 protein or lactate dehydrogenase (LDH)], and with a trend for higher frequency of adverse events (AEs). An increase in average 25(OH)D s.c. of 1 ng/ml was associated with a 3.9% reduced risk for progressive disease [hazard ratio (HR) = 0.961, p = 0.044], with a reduction of LDH s.c. of 3.86 U/l (p = 0.034, indicating a reduction of TL), and with a trend for reduced frequency of AEs (AE ratio -0.005; p = 0.295). Patients with average 25(OH)D s.c. ≥10 ng/ml and BRAF-mutant melanoma showed a trend for a higher frequency of AEs as compared to individuals with BRAF wild-type melanomas. Our data indicate that vitamin D deficiency is associated with poor clinical outcome in patients treated for metastasized melanoma with BRAF/MEK inhibitors or immunotherapy. Although it needs to be proven in future interventional trials whether optimizing serum 25(OH)D improves clinical outcome in these patients, we recommend that 25(OH)D s.c. should be analyzed and vitamin D deficiency treated in all patients with advanced melanoma.
DOI of the first publication: 10.3389/fonc.2022.839816
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-397802
ISSN: 2234-943X
Date of registration: 16-May-2023
Faculty: M - Medizinische Fakultät
Department: M - Dermatologie
M - Medizinische Biometrie, Epidemiologie und medizinische Informatik
Professorship: M - Prof. Dr. Thomas Vogt
M - Prof. Dr. Stefan Wagenpfeil
M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
fonc-12-839816.pdf2,15 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons